Overall, this suggests that transient inhibition of JAK1/2 signalling reduces the engraftment barrier presented by residual recipient NK and T cells, allowing full donor engraftment, whilst improving GVT and decreasing priming of acute GVHD onset. This evidence concerns the gene JAK1 and graft versus host disease.